Christiansburg, VA, United States of America

James Hunter Boone

This inventor holds 13 USPTO granted patents and 4 published patent applications, plus 3 CIPO patents and 2 EPO patents. Top assignee: Techlab, Inc.. Active years: 2005-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: James Hunter Boone. Retrieved from https://idiyas.com/inventor/james-hunter-boone

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 13 (Patent Applications = 4)

% Patents Active = 100.0

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 3.5

ph-index = 3

Forward Citations = 35(Granted Patents)

Location History:

Christiansburg, VA (US) (2005 - 2019)
Christianburg, VA (US) (2019)

Company Filing History:

13 out of 18

Techlab, Inc.

patents

Years Active: 2005-2019

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10295536 - [object Object] (2019-05-21),

2. 10295535 - Clostridium difficile dehydrogenase and toxin as a biomarker for monitoring infection in patients with clostridium difficile disease and differentiating carrier state from active disease (2019-05-21),

3. 10196632 - Nucleic acid extraction using organic solvents to remove inhibitors (2019-02-05),

4. 9528105 - Nucleic acid extraction using organic solvents to remove inhibitors (2016-12-27),

5. 9274112 - Device and method for detection of analytes (2016-03-01),

6. 8541242 - Device and method for detection of analytes (2013-09-24),

7. 8343726 - Device and method for detection of analytes (2013-01-01),

8. 7892762 - Method for diagnosing irritable bowel syndrome and monitoring inflammatory bowel disease (2011-02-22),

9. 7785818 - Inflammatory bowel disease and irritable bowel syndrome IBD-first chek diagnostic panel (2010-08-31),

10. 7736858 - Method for distinguishing ulcerative colitis from Crohn's disease by detecting the presence of fecal anit-neutrophil cytoplasmic antibodies (ANCA) (2010-06-15),

11. 7560240 - Method for monitoring gastrointestinal inflammation in persons with inflammatory bowel disease(IBD) (2009-07-14),

12. 7192724 - Method for differentiating irritable bowel syndrome from inflammatory bowel disease (IBD) and for monitoring persons with IBD using total endogenous lactoferrin as a marker (2007-03-20),

13. 6872540 - Method and apparatus for distinguishing Crohn's disease from ulcerative colitis and other gastrointestinal diseases by detecting the presence of fecal antibodies to Saccharomyces cerevisiae (2005-03-29),

Title: Innovations of James Hunter Boone

Introduction

James Hunter Boone is a notable inventor based in Christiansburg, VA (US). He has made significant contributions to the field of medical diagnostics, particularly in relation to Clostridium difficile infections. With a total of 13 patents to his name, Boone's work has the potential to greatly impact patient care and treatment outcomes.

Latest Patents

One of Boone's latest patents focuses on the use of Clostridium difficile dehydrogenase and toxin as a biomarker for monitoring infection in patients. This innovation is crucial for differentiating between carrier states and active disease. The disease presents a range of clinical symptoms, from mild diarrhea to severe conditions like pseudomembranous colitis and megacolon. Treatment varies based on the severity of the disease, with mild cases often managed with metronidazole, while severe cases may require vancomycin or fidaxomicin. Current molecular assays are sensitive but cannot definitively rule out carrier status. Boone's biomarker panel, which includes GDH, toxins A and B, and fecal lactoferrin, allows clinicians to make more informed decisions regarding treatment and monitoring.

Career Highlights

Boone is currently employed at Techlab, Inc., where he continues to develop innovative solutions for medical diagnostics. His work has been instrumental in advancing the understanding and management of Clostridium difficile infections.

Collaborations

Throughout his career, Boone has collaborated with esteemed colleagues such as David Maxwell Lyerly and Tracy Dale Wilkins. These partnerships have fostered a collaborative environment that enhances the development of groundbreaking medical technologies.

Conclusion

James Hunter Boone's contributions to the field of medical diagnostics, particularly regarding Clostridium difficile infections, highlight his innovative spirit and dedication to improving patient care. His work continues to pave the way for advancements in medical technology and treatment strategies.

Profile summary based on public USPTO records.